Artivion (AORT) Stock Price, News & Analysis

Company Overview

Artivion, Inc. (NYSE: AORT) is a global medical device company specializing in the development, manufacturing and marketing of advanced surgical technologies for the treatment of cardiovascular and vascular diseases. The company’s core offerings include biologic implants, synthetic grafts and surgical sealants designed to improve patient outcomes in complex cardiac and vascular procedures. Artivion’s product portfolio addresses a broad range of clinical needs such as aortic aneurysm repair, structural heart disease and peripheral vascular reconstruction.

Artivion’s biologic implant line leverages proprietary tissue processing techniques to create decellularized vascular and soft tissue grafts that offer enhanced biocompatibility and long-term durability. Its synthetic graft products feature woven and knitted materials engineered for high burst strength and flexibility, while its sealant solutions provide hemostatic support to reduce bleeding and postoperative complications. The company continuously invests in research and development to advance its next-generation portfolio, focusing on minimally invasive delivery methods and regenerative medicine approaches.

Founded in Birmingham, Alabama, in 1965, Artivion has grown both organically and through strategic acquisitions to establish a presence in more than 50 countries. The company operates manufacturing and distribution facilities across North America, Europe and Asia, with a sales and clinical support organization dedicated to collaborating with hospitals, surgeons and academic institutions worldwide. Artivion’s global footprint enables it to address the unique regulatory and clinical requirements of diverse markets.

Artivion’s leadership team is headed by President and Chief Executive Officer Frank J. Madden Jr., whose background in medical technology and private equity has guided the company through significant transformation and growth. Under his direction, Artivion has sharpened its strategic focus on innovative product development, streamlined operations and expanded commercial capabilities. The company remains committed to partnering with healthcare professionals to advance surgical care and improve patient quality of life.

Key Stats

• Today's Range: $30.48 to $31.52
• 50-Day Range: $23.36 to $31.17
• 52-Week Range: $21.97 to $32.33
• Volume: 189,380 shs
• Average Volume: 337,182 shs
• Market Capitalization: $1.35 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.40
• Consensus Rating: Buy

Artivion Stock Analysis - MarketRank™

Artivion scored higher than 55% of companies evaluated by MarketBeat, and ranked 459th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.6 / 5
• Analyst Rating: Buy

Consensus Rating

Artivion has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Artivion has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 35.14%

Earnings Growth

Earnings for Artivion are expected to grow by 35.14% in the coming year, from $0.37 to $0.50 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Artivion is -63.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Artivion is -63.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Artivion has a P/B Ratio of 4.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.82% of the float of Artivion has been sold short.

Short Interest Ratio / Days to Cover

Artivion has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Artivion has recently decreased by 3.80%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Artivion does not currently pay a dividend.

Dividend Growth

Artivion does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.82% of the float of Artivion has been sold short.

Short Interest Ratio / Days to Cover

Artivion has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Artivion has recently decreased by 3.80%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: N/A

News Sentiment

Artivion has a news sentiment score of 1.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Artivion this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for AORT on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Artivion to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,108,525.00 in company stock.

Percentage Held by Insiders

Only 8.10% of the stock of Artivion is held by insiders.

Percentage Held by Institutions

86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AORT Stock Analysis - Frequently Asked Questions

How have AORT shares performed this year?

Artivion's stock was trading at $28.59 on January 1st, 2025. Since then, AORT shares have increased by 10.2% and is now trading at $31.5050.

How were Artivion's earnings last quarter?

Artivion, Inc. (NYSE:AORT) posted its quarterly earnings data on Monday, May, 5th. The company reported $0.06 earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by $0.06. The firm had revenue of $98.98 million for the quarter, compared to the consensus estimate of $94.81 million. Artivion had a negative net margin of 5.49% and a positive trailing twelve-month return on equity of 3.63%.
Read the conference call transcript.

How do I buy shares of Artivion?

Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Artivion own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Artivion investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:AORT
• CIK: 784199
• Web: www.cryolife.com
• Phone: (770) 419-3355
• Fax: 770-426-0031
• Employees: 1,600
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Artivion: $32.40
• High Price Target: $35.00
• Low Price Target: $30.00
• Potential Upside/Downside: +5.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 82.68
• P/E Growth: N/A
• Net Income: -$13.36 million
• Net Margins: -5.49%
• Pretax Margin: -5.79%
• Return on Equity: 3.63%
• Return on Assets: 1.34%

Debt

• Debt-to-Equity Ratio: 1.08
• Current Ratio: 5.53
• Quick Ratio: 3.95

Sales & Book Value

• Annual Sales: $388.54 million
• Price / Sales: 3.36
• Cash Flow: $0.84 per share
• Price / Cash Flow: 36.31
• Book Value: $6.59 per share
• Price / Book: 4.64

Miscellaneous

• Outstanding Shares: 42,700,000
• Free Float: 39,244,000
• Market Cap: $1.31 billion
• Optionable: Optionable
• Beta: 1.62